Search Results - "Burg, Sjoerd H."

Therapeutic cancer vaccines by Saxena, Mansi, van der Burg, Sjoerd H., Melief, Cornelis J. M., Bhardwaj, Nina

“…Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better understanding of the breadth of tumour-associated antigens, the native…”
Get full text

Monalizumab: inhibiting the novel immune checkpoint NKG2A by van Hall, Thorbald, André, Pascale, Horowitz, Amir, Ruan, Dan Fu, Borst, Linda, Zerbib, Robert, Narni-Mancinelli, Emilie, van der Burg, Sjoerd H., Vivier, Eric

“…The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an…”
Get full text

Identification and manipulation of tumor associated macrophages in human cancers by Heusinkveld, Moniek, van der Burg, Sjoerd H

“…Evading immune destruction and tumor promoting inflammation are important hallmarks in the development of cancer. Macrophages are present in most human tumors…”
Get full text

Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study by Mandruzzato, Susanna, Brandau, Sven, Britten, Cedrik M., Bronte, Vincenzo, Damuzzo, Vera, Gouttefangeas, Cécile, Maurer, Dominik, Ottensmeier, Christian, van der Burg, Sjoerd H., Welters, Marij J. P., Walter, Steffen

“…There is an increasing interest for monitoring circulating myeloid-derived suppressor cells (MDSCs) in cancer patients, but there are also divergences in their…”
Get full text

The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment by Borst, Linda, van der Burg, Sjoerd H, van Hall, Thorbald

“…The success of checkpoint blockade therapy revolutionized cancer treatment. However, we need to increase the fraction of responding patients and overcome…”
Get full text

NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division by Borst, Linda, Sluijter, Marjolein, Sturm, Gregor, Charoentong, Pornpimol, Santegoets, Saskia J., Gulijk, Mandy, Elsas, Marit J., Groeneveldt, Christianne, Montfoort, Nadine, Finotello, Francesca, Trajanoski, Zlatko, Kiełbasa, Szymon M., Burg, Sjoerd H., Hall, Thorbald

“…The surface inhibitory receptor NKG2A forms heterodimers with the invariant CD94 chain and is expressed on a subset of activated CD8 T cells. As antibodies to…”
Get full text

Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T‐cell activation by Rosalia, Rodney A., Quakkelaar, Esther D., Redeker, Anke, Khan, Selina, Camps, Marcel, Drijfhout, Jan W., Silva, Ana Luisa, Jiskoot, Wim, Hall, Thorbald, Veelen, Peter A., Janssen, George, Franken, Kees, Cruz, Luis J., Tromp, Angelino, Oostendorp, Jaap, Burg, Sjoerd H., Ossendorp, Ferry, Melief, Cornelis J. M.

“…The efficiency of antigen (Ag) processing by dendritic cells (DCs) is vital for the strength of the ensuing T‐cell responses. Previously, we and others have…”
Get full text

Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement by Marijt, Koen A., Griffioen, Lisa, Blijleven, Laura, van der Burg, Sjoerd. H., van Hall, Thorbald

“…Cancer cells frequently display defects in their antigen-processing pathway and thereby evade CD8 T cell immunity. We described a novel category of cancer…”
Get full text

Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer by Welters, Marij J P, Ma, Wenbo, Santegoets, Saskia J A M, Goedemans, Renske, Ehsan, Ilina, Jordanova, Ekaterina S, van Ham, Vanessa J, van Unen, Vincent, Koning, Frits, van Egmond, Sylvia I, Charoentong, Pornpimol, Trajanoski, Zlatko, van der Velden, Lilly-Ann, van der Burg, Sjoerd H

“…Human papillomavirus (HPV)-associated oropharyngeal squamous cell cancer (OPSCC) has a much better prognosis than HPV-negative OPSCC, and this is linked to…”
Get full text

Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer by Kverneland, Anders Handrup, Pedersen, Magnus, Westergaard, Marie Christine Wulff, Nielsen, Morten, Borch, Troels Holz, Olsen, Lars Rønn, Aasbjerg, Gitte, Santegoets, Saskia J., Burg, Sjoerd H. van der, Milne, Katy, Nelson, Brad H., Met, Özcan, Donia, Marco, Svane, Inge Marie

“…Immune therapy is a promising field within oncology but has been unsuccessful in ovarian cancer (OC). Still, there is rationale and evidence supporting immune…”
Get full text

Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients by Hurkmans, Daan P., Kuipers, Merian E., Smit, Jasper, van Marion, Ronald, Mathijssen, Ron H. J., Postmus, Piet E., Hiemstra, Pieter S., Aerts, Joachim G. J. V., von der Thüsen, Jan H., van der Burg, Sjoerd H.

“…Objectives A minority of NSCLC patients benefit from anti-PD1 immune checkpoint inhibitors. A rational combination of biomarkers is needed. The objective was…”
Get full text

Vaccines for established cancer: overcoming the challenges posed by immune evasion by van der Burg, Sjoerd H., Arens, Ramon, Ossendorp, Ferry, van Hall, Thorbald, Melief, Cornelis J. M.

“…Key Points Therapeutic vaccines for the induction of tumour-specific T cell responses show high immunogenicity and clinical efficacy over different formulation…”
Get full text

Interleukin‐6‐mediated resistance to immunotherapy is linked to impaired myeloid cell function by Beyranvand Nejad, Elham, Labrie, Camilla, Sluis, Tetje C., Duikeren, Suzanne, Franken, Kees L. M. C., Roosenhoff, Rueshandra, Arens, Ramon, Hall, Thorbald, Burg, Sjoerd H.

“…High serum levels of interleukin‐6 (IL‐6) correlate with poor prognosis and chemotherapy resistance in several cancers. The underlying mechanisms and its…”
Get full text

Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry by Santegoets, Saskia J. A. M., Dijkgraaf, Eveline M., Battaglia, Alessandra, Beckhove, Philipp, Britten, Cedrik M., Gallimore, Awen, Godkin, Andrew, Gouttefangeas, Cecile, de Gruijl, Tanja D., Koenen, Hans J. P. M., Scheffold, Alexander, Shevach, Ethan M., Staats, Janet, Taskén, Kjetil, Whiteside, Theresa L., Kroep, Judith R., Welters, Marij J. P., van der Burg, Sjoerd H.

“…Regulatory T cell (Treg)-mediated immunosuppression is considered a major obstacle for successful cancer immunotherapy. The association between clinical…”
Get full text

Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response by Karim, Rezaul, Tummers, Bart, Meyers, Craig, Biryukov, Jennifer L, Alam, Samina, Backendorf, Claude, Jha, Veena, Offringa, Rienk, van Ommen, Gert-Jan B, Melief, Cornelis J M, Guardavaccaro, Daniele, Boer, Judith M, van der Burg, Sjoerd H

“…Persistent infection of basal keratinocytes with high-risk human papillomavirus (hrHPV) may cause cancer. Keratinocytes are equipped with different pattern…”
Get full text

Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma by Bronkhorst, Inge H G, Vu, T H Khanh, Jordanova, Ekaterina S, Luyten, Gregorius P M, Burg, Sjoerd H van der, Jager, Martine J

“…In contrast to many other malignancies, in uveal melanoma (UM) the presence of an immune infiltrate is associated with a bad prognosis. An analysis of the…”
Get full text

Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses by Groeneveldt, Christianne, van Hall, Thorbald, van der Burg, Sjoerd H., ten Dijke, Peter, van Montfoort, Nadine

“…In cancer immunotherapy, a patient’s own immune system is harnessed against cancer. Immune checkpoint inhibitors release the brakes on tumor-reactive T cells…”
Get full text

The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancer by Santegoets, Saskia J., Welters, Marij J. P., Schrikkema, Deborah S., Freriks, Manon R., Kok, Hanna, Weissbrich, Bianca, van den Branden, Anouk, Linnemann, Carsten, Schumacher, Ton N., Adhikary, Sabina, Bendle, Gavin, van der Burg, Sjoerd H.

“…Immunotherapies targeting truly tumor-specific targets focus on the expansion and activation of T cells against neoantigens or oncogenic viruses. One target is…”
Get full text

A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence by Kaplon, Joanna, Zheng, Liang, Meissl, Katrin, Chaneton, Barbara, Selivanov, Vitaly A., Mackay, Gillian, van der Burg, Sjoerd H., Verdegaal, Elizabeth M. E., Cascante, Marta, Shlomi, Tomer, Gottlieb, Eyal, Peeper, Daniel S.

“…Pyruvate dehydrogenase (PDH) is identified as a crucial mediator of BRAF V600E -induced cellular senescence: PDH is activated by BRAF-mediated suppression of…”
Get full text

Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling by Marijt, Koen A, Sluijter, Marjolein, Blijleven, Laura, Tolmeijer, Sofie H, Scheeren, Ferenc A, van der Burg, Sjoerd H, van Hall, Thorbald

“…T-cell mediated immunotherapy brought clinical success for many cancer patients. Nonetheless, downregulation of MHC class I antigen presentation, frequently…”
Get full text